- Home
- DMB vs CDXS Comparison
DMB vs CDXS Comparison
Compare DMB & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMB
- CDXS
- Stock Information
- Founded
- DMB 2013
- CDXS 2002
- Country
- DMB United States
- CDXS United States
- Employees
- DMB N/A
- CDXS N/A
- Industry
- DMB Trusts Except Educational Religious and Charitable
- CDXS Major Chemicals
- Sector
- DMB Finance
- CDXS Industrials
- Exchange
- DMB Nasdaq
- CDXS Nasdaq
- Market Cap
- DMB 181.7M
- CDXS 201.3M
- IPO Year
- DMB N/A
- CDXS 2010
- Fundamental
- Price
- DMB $9.96
- CDXS $2.33
- Analyst Decision
- DMB
- CDXS Buy
- Analyst Count
- DMB 0
- CDXS 2
- Target Price
- DMB N/A
- CDXS $11.00
- AVG Volume (30 Days)
- DMB 76.6K
- CDXS 992.6K
- Earning Date
- DMB 01-01-0001
- CDXS 05-14-2025
- Dividend Yield
- DMB 4.17%
- CDXS N/A
- EPS Growth
- DMB N/A
- CDXS N/A
- EPS
- DMB N/A
- CDXS N/A
- Revenue
- DMB N/A
- CDXS $49,815,000.00
- Revenue This Year
- DMB N/A
- CDXS $2.41
- Revenue Next Year
- DMB N/A
- CDXS $34.28
- P/E Ratio
- DMB N/A
- CDXS N/A
- Revenue Growth
- DMB N/A
- CDXS N/A
- 52 Week Low
- DMB $8.94
- CDXS $1.90
- 52 Week High
- DMB $11.79
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- DMB 37.78
- CDXS 46.61
- Support Level
- DMB $9.97
- CDXS $2.20
- Resistance Level
- DMB $10.07
- CDXS $2.56
- Average True Range (ATR)
- DMB 0.09
- CDXS 0.19
- MACD
- DMB -0.02
- CDXS -0.01
- Stochastic Oscillator
- DMB 1.52
- CDXS 60.32
About DMB BNY Mellon Municipal Bond Infrastructure Fund Inc.
BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.